Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial
Open Access
- 26 October 2020
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 43 (12) , 1592-1600
Abstract
Background: Atrial fibrillation (AF) is a complex cardiac arrhythmia in clinical practice with increasing incidence. However, the effects of statins on patients with AF are not quite clear.Hypothesis: To investigate the protective effect of calcium channel blocker (CCB) and valsartan combined fluvastatin on hypertension (HTN) patients with nonpermanent AF.Methods: In three and a half years, 189 cases of patients diagnosed as HTN combining nonpermanent AF by eight medical centers, were recruited and randomly assigned to four groups with varied treatments: CCB group; CCB + statin group; valsartan group; and valsartan + statin group. The four groups were followed up for 24 months. The 7‐day Holter ultrasound echocardiography (UCG) and biochemical indexes were completed at preset time nodes respectively.Results: After 24 months of follow‐up, 178 patients completed the study. Compared with CCB group, the blood lipid level, inflammatory index, ultrasonic index and electrocardiographic measurement results of CCB + statin group, valsartan group and valsartan + statin group were improved in different degrees and had statistical significance (P < .05 or P < .01). Furthermore, the improvement trend of CCB + statin group and valsartan + statin group was more obvious.Conclusions: The results indicated that valsartan can reduce AF load and recurrence rate, and delay the progression of nonpermanent AF to permanent AF in multiple ways, and the effect of combination of valsartan and fluvastatin is more significant. These results provide a new direction for the integrated upstream control strategy of AF.Keywords
Funding Information
- National Natural Science Foundation of China (81370300)
This publication has 30 references indexed in Scilit:
- Searching for Atrial Fibrillation PoststrokeCirculation, 2019
- Mechanisms of atrial fibrillationHeart, 2019
- Increasing trends in hospitalisations due to atrial fibrillation in Australia from 1993 to 2013Heart, 2019
- Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial FibrillationCirculation, 2019
- Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial FibrillationCirculation, 2018
- Lifestyle Modification in the Prevention and Treatment of Atrial FibrillationProgress in Cardiovascular Diseases, 2015
- Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trialTrials, 2015
- Targeting Inflammation and Oxidative Stress in Atrial Fibrillation: Role of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibition with StatinsAntioxidants & Redox Signaling, 2014
- A Rising TideCirculation, 2014
- Atrial FibrillationCirculation, 2011